We are live on ! Find out more

Supernus Pharmaceuticals

SUPN

Market cap $2.44B

41.92 USD

+0.08

0.19%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

41.92

0.00

0%

1 day

0.19%

5 days

2.95%

1 month

-2.6%

3 months

-8.09%

6 months

-12.67%

Year to date

-15.26%

1 year

-25.81%

5 years

38.17%

10 years

111.72%

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Employees: 778

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 57.6%

Negative 9.1%

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Supernus Pharmaceuticals Q3 Earnings Call Highlights

Supernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals.

Supernus Pharmaceuticals Q3 Earnings Call Highlights

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.

Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript

Supernus Announces Third Quarter 2026 Financial Results

ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.

Supernus Announces Third Quarter 2026 Financial Results

Zacks Investment Research

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover

Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue, with Qelbree and ZURZUVAE driving robust prescription and sales growth. Combined entity targets $2.2B revenue, $888M adjusted EBITDA, $125M synergies, and trades at ~7x synergized EBITDA—suggesting a mispriced, underappreciated value.

Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether thi.

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

See News Rankings

Price charts implemented using Lightweight Charts™